Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 14/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12462194 | 0.92 | TSHR (0.51) | TSHRACHEMEN1KMT2AALDH1A1 | |
| SCHEMBL17658797 | 0.86 | TSHR (0.54) | TSHRMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL4138562 | 0.85 | TSHR (0.48) | TSHRACHEMEN1KMT2AALDH1A1 | |
| SCHEMBL20117523 | 0.85 | TSHR (0.50) | TSHRMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL1753633 | 0.85 | TSHR (0.53) | TSHRMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL1022208 | 0.84 | TSHR (0.67) | TSHRACHE | |
| SCHEMBL16541276 | 0.84 | TSHR (0.56) | TSHRACHEMEN1KMT2AALDH1A1 | |
| SCHEMBL19975633 | 0.83 | TSHR (0.66) | TSHRACHE | |
| SCHEMBL13647776 | 0.83 | TSHR (0.68) | TSHRALDH1A1MAPT | |
| SCHEMBL410380 | 0.83 | TSHR (0.48) | TSHRACHEMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11828913-B2 | Silicone hydrogels comprising polyamides | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20210141122-A1 | SILICONE HYDROGELS COMPRISING POLYAMIDES | JOHNSON & JOHNSON VISION CARE (US) | 2021-05-13 | — | — | US | disclosed |
| US-9914273-B2 | Method for using a stacked integrated component media insert in an ophthalmic device | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-9880398-B2 | Method and apparatus for ophthalmic devices including gradient-indexed and shaped liquid crystal layers | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9804416-B2 | Energizable ophthalmic lens with an event-based coloration system | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9612363-B2 | Silicone hydrogel reactive mixtures comprising borates | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20170090215-A9 | METHOD AND APPARATUS FOR OPHTHALMIC DEVICES INCLUDING GRADIENT-INDEXED AND SHAPED LIQUID CRYSTAL LAYERS | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9541772-B2 | Methods and apparatus for ophthalmic devices including cycloidally oriented liquid crystal layers | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9448421-B2 | Ophthalmic lens system capable of communication between lenses utilizing a secondary external device | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9427920-B2 | Energized media for an ophthalmic device | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-7956131-B2 | Lactam polymer derivatives | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20110045112-A1 | VARIABLE FOCUS OPHTHALMIC DEVICE | JOHNSON & JOHNSON VISION CARE, INC. | 2011-02-24 | — | — | US | disclosed |
| US-20100171923-A1 | LACTAM POLYMER DERIVATIVES | JOHSNON & JOHNSON VISION CARE, INC. | 2010-07-08 | — | — | US | disclosed |
| US-20100151123-A1 | WETTABLE HYDROGELS COMPRISING ACYCLIC POLYAMIDES | JOHNSON & JOHNSON VISION CARE, INC. | 2010-06-17 | — | — | US | disclosed |
| US-20100078838-A1 | ENERGIZED MEDIA FOR AN OPHTHALMIC DEVICE | JOHNSON & JOHNSON VISION CARE, INC. | 2010-04-01 | — | — | US | disclosed |
| US-20090321970-A1 | OPHTHALMIC LENS MOLDS PARTS WITH SILOXANE WAX | JOHNSON & JOHNSON VISION CARE, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090243125-A1 | METHODS AND APPARATUS FOR INK JET PROVIDED ENERGY RECEPTOR | JOHNSON & JOHNSON VISION CARE, INC. | 2009-10-01 | — | — | US | disclosed |
| US-7461937-B2 | Soft contact lenses displaying superior on-eye comfort | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20080114123-A1 | Anionic polymers having sulfonate, sulfate, phosphonate, phosphate or borate grouops capable of acting as osmotic drivers for contact lenses and medical equipment; maintaining a desired water balance by moving water in or out of a substrate; hydration; wetting agents; coatings; stents; bandages | JOHNSON & JOHNSON VISION CAR, INC | 2008-05-15 | — | — | US | disclosed |
| US-7247692-B2 | Biomedical devices containing amphiphilic block copolymers | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2007-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100151123-A1 | WETTABLE HYDROGELS COMPRISING ACYCLIC POLYAMIDES | CRYAA, UACA, CRYZ | TSHR 3880/4885ACHE 1993/4885MEN1 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.